Repaso Abo%5 B1%5 D.D 24.9.07%28dra.Basatos%29

Sistema ABO Dra. Fabiana Bastos [email_address] Departamento de Hemoterapia e Inmunohematología Hospital de Clínicas “José de San Martín”

PERSPECTIVA HISTORICA ,[object Object],[object Object],[object Object]

PERSPECTIVA HISTORICA ,[object Object],[object Object]

HERENCIA ,[object Object],[object Object]

HERENCIA ,[object Object],[object Object],[object Object],[object Object],[object Object]

FORMACION DE ANTIGENOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FORMACION DE ANTIGENOS ,[object Object],[object Object],[object Object],[object Object]

FORMACION DE ANTIGENOS β 1->4

FORMACION DE ANTIGENOS B D-galactosa α -3-D-galactosiltransferasa B A N-acetil-galactosamina α -3-N-acetilgalactosaminil-transferasa A H L-fucosa α -2-L-fucosiltransferasa H Antígeno Azúcar inmunodominante Glicosiltransferasa Gen

GENETICA MOLECULAR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],ANTIGENOS

ANTIGENOS ,[object Object],[object Object],[object Object],[object Object]

ANTIGENOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ANTIGENOS SOLUBLES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ANTIGENOS SOLUBLES ,[object Object],[object Object],[object Object],[object Object],[object Object]

ANTIGENOS SOLUBLES ,[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

REACTIVOS ANTI-A y ANTI-H ,[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS A ,[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS A ,[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS A ,[object Object],[object Object]

SUBGRUPOS DEBILES DE A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE A ,[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE A ,[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE A ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE B ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SUBGRUPOS DEBILES DE B ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FENOTIPO BOMBAY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FENOTIPO BOMBAY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FENOTIPO BOMBAY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CAUSAS DE ERROR ,[object Object],[object Object],[object Object],[object Object]

GRUPO 1 Pérdida de reactividad del anticuerpo ,[object Object],[object Object],[object Object],[object Object],[object Object]

GRUPO 1 Pérdida de reactividad del anticuerpo ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

GRUPO 1 Resolución ,[object Object],[object Object],[object Object],[object Object],[object Object]

GRUPO 2 Pérdida de reactividad del antígeno ,[object Object],[object Object],[object Object]

GRUPO 2 Resolución ,[object Object],[object Object],[object Object]

GRUPO 2 Resolución ,[object Object],[object Object]

GRUPO 3 Anormalidades plasmáticas ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

GRUPO 3 Resolución ,[object Object],[object Object]

GRUPO 4 Anticuerpos adicionales ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

GRUPO 4 Resolución ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Repaso Abo%5 B1%5 D.D 24.9.07%28dra.Basatos%29

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Destacado

Destacado (7)

Similar a Repaso Abo%5 B1%5 D.D 24.9.07%28dra.Basatos%29

Similar a Repaso Abo%5 B1%5 D.D 24.9.07%28dra.Basatos%29 (20)

Más de lucasmerel

Más de lucasmerel (20)

Último

Último (20)

Repaso Abo%5 B1%5 D.D 24.9.07%28dra.Basatos%29